Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclacumab in sickle cell disease with vaso-occlusive crises
NCT04935879Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of inclacumab in sickle cell disease (SCD), sponsored by Pfizer. Started Oct 2021; status: completed.
02
Drugs
inclacumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04935879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935879.